Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Lantern Pharma Inc (NQ: LTRN )

4.580 +0.040 (+0.88%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 22,814
Open 4.630
Bid (Size) 4.580 (3)
Ask (Size) 4.700 (3)
Prev. Close 4.540
Today's Range 4.530 - 4.882
52wk Range 2.380 - 11.99
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Lantern Pharma Achieves Key Milestone Towards Development of Molecular Diagnostic for use in Oncology Clinical Trials for Patient Selection and Stratification with Drug Candidate LP-184
From Lantern Pharma
Via Business Wire
Lantern Pharma Receives Certificate of Patent from Japanese Patent Office (JPO) for Composition of Matter Covering Drug Candidate LP-284
From Lantern Pharma Inc.
Via Business Wire

Performance

YTD
+9.83%
+9.83%
1 Month
+0.88%
+0.88%
3 Month
-7.10%
-7.10%
6 Month
+8.02%
+8.02%
1 Year
+0.03%
+0.03%

More News

Read More
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Recap: Lantern Pharma Q4 Earnings
Via Benzinga
Lantern Pharma Earnings Preview
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
LTRN Stock Earnings: Lantern Pharma Misses EPS for Q1 2024
Via InvestorPlace
Lantern Pharma Reports First Quarter 2024 Financial Results and Business Highlights
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma to Report First Quarter 2024 Operating & Financial Results on May 9th, 2024 at 4:30 p.m. ET
From Lantern Pharma Inc.
Via Business Wire
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism
From Lantern Pharma Inc.
Via Business Wire
3 Machine Learning Stocks with the Potential to Make You an Overnight Millionaire
Via InvestorPlace
Lantern Pharma Launches “Webinar Wednesdays” Featuring World-Class Physician Scientists & Key Opinion Leaders Discussing Critical Areas of Oncology Drug Development
From Lantern Pharma Inc.
Via Business Wire
Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan
From Lantern Pharma Inc.
Via Business Wire
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Software Segment of Global A.I. Healthcare Billion Dollar Market Expected to Have Fastest Growth
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
AI Sector Stalling: Only 4 Of 7 Categories Went Up In March
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Six Of Seven AI Stock Categories Increased This Week
Via Talk Markets
Topics Artificial Intelligence
Exposures Artificial Intelligence
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
Via FinancialNewsMedia
Topics Artificial Intelligence
Exposures Artificial Intelligence
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
LTRN Stock Earnings: Lantern Pharma Beats EPS for Q4 2023
Via InvestorPlace
Global A.I. Medical Diagnostics Market Poised To Reach $3.7 Billion By 2028
From FN Media Group LLC
Via GlobeNewswire
Lantern Pharma Reports Fourth Quarter & Fiscal Year 2023 Financial Results and Business Highlights
From Lantern Pharma Inc.
Via Business Wire
Earnings Scheduled For March 18, 2024
Via Benzinga
Lantern Pharma Announces Initial Patients Dosed in First-In-Human Clinical Trial for AI-Guided Drug-Candidate, LP-284
From Lantern Pharma Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.